Skip to main content

Articles

Payers' Guide, FDA Approvals

Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Lung Cancer, Payers' Guide, FDA Approvals, Oncology

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Payers' Guide, FDA Approvals

Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma

Payers' Guide, FDA Approvals

Aliqopa (Copanlisib), an Intravenous PI3K Inhibitor, Approved for Patients with Relapsed Follicular Lymphoma

Payers' Guide, FDA Approvals

Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis

Payers' Guide, FDA Approvals

Xadago (Safinamide), an Oral MAO-B Inhibitor, FDA Approved as Adjunctive Treatment for Patients with Parkinson’s Disease

Payers' Guide, FDA Approvals

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Payers' Guide, FDA Approvals

Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Payers' Guide, FDA Approvals

Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma

Payers' Guide, FDA Approvals

Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy

Page 74 of 245
Results 731 - 740 of 2441